1 rich Libsyn https://www.libsyn.com 90 600 Current and emergent incretin-based therapies (such as GLP-1 and GIP receptor agonists) have transformed obesity treatment by producing unprecedented weight loss. But these benefits come with complexity: significant lean mass loss, raising concerns about metabolic stability, muscle health, and long-term outcomes.&amp;nbsp; &amp;nbsp; In this episode, we briefly revisit the clinical approach to weight-loss medications, connect the foundations of leptin dysregulation with leptin-independent pathways (including the activin/follistatin/myostatin/IGF-1 system), and link these pathways to energy homeostasis and muscle maintenance. We also discuss strategies to preserve lean mass during significant pharmacologically-induced weight reduction. Fireside Chats on Endocrinology and Metabolism in the Mantzoros lab https://sites.libsyn.com/422864 <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/39144195/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/195753035